Gésily de Souza Aguiar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gésily de Souza Aguiar has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Helene Nara Henriques Blanc
Universidade Federal do Rio de Janeiro, Brazil
2 shared publications - Kênia Moreno de Oliveira
Universidade Estadual de Campinas (UNICAMP)
2 shared publications - Rosane Aparecida Ribeiro
Universidade Estadual de Ponta Grossa (UEPG)
2 shared publications - Ana Beatriz Barbosa da Silva1 shared publication
- Everardo Magalhães Carneiro
Universidade Estadual de Campinas (UNICAMP)
1 shared publication - Israelle Netto Freitas
Universidade Federal do Rio de Janeiro, Brazil
1 shared publication
Latest Publications
- Open Access
- 14 January 2025
- Published by Universidade Estadual do Ceará in Nutrivisa - Revista de Nutrição e Vigilância em Saúde
- Vol. 12 (1) , e15667
Effects of continuous ethinylestradiol and drospirenone administration on body mass and mammary gland in female mice fed a standard or high-fat diet
Combined oral contraception (COC) is used by millions of women worldwide, but some studies suggest it may increase the risk of breast cancer. Overweight and obesity have reached epidemic levels and are also risk factors for mammary gland neoplasms. This study evaluated the effects of a COC containing ethinylestradiol (EE2) and drospirenone (DRSP) on reproductive organs, particularly the histopathology of inguinal mammary glands in reproductively active female mice fed a standard diet (SD) or high-fat diet (HFD). Adult Swiss female mice received either SD or HFD and were treated daily by gavage with distilled water [control (CTL)-SD and CTL-HFD] or 0.6 µg EE2 and 60 µg DRSP (COC-SD and COC-HFD) for 65 days. COC treatment disrupted the estrous cycle, with vaginal smears showing fewer squamous cornified cells but more leukocytes, deep cells, and mucus, characteristic of metestrus and proestrus. At the end of the experiment, COC-SD females showed body weight (BW), inguinal white adipose tissue (WAT) mass, and uterus and ovary weights similar to CTL-SD. HFD increased BW and WAT mass without altering uterus and ovary weights. COC reduced HFD-induced BW and WAT gain but increased uterus weight in COC-HFD females. Morphological analysis of mammary glands revealed no pathological signs or structural changes in acini, ducts, or lumens due to COC or diet. Notably, COC-HFD females had smaller white adipocytes than CTL-HFD, while beige adipocyte levels remained unchanged across groups. These findings suggest that EE2 and DRSP may regulate HFD-induced obesity without adversely affecting mammary gland morphology.
- 14 January 2025
- Published by Universidade Estadual do Ceará in Nutrivisa - Revista de Nutrição e Vigilância em Saúde
- Vol. 12 (1) , e15667
Open AccessEffects of continuous ethinylestradiol and drospirenone administration on body mass and mammary gland in female mice fed a standard or high-fat diet
Combined oral contraception (COC) is used by millions of women worldwide, but some studies suggest it may increase the risk of breast cancer. Overweight and obesity have reached epidemic levels and are also risk factors for mammary gland neoplasms. This study evaluated the effects of a COC containing ethinylestradiol (EE2) and drospirenone (DRSP) on reproductive organs, particularly the histopathology of inguinal mammary glands in reproductively active female mice fed a standard diet (SD) or high-fat diet (HFD). Adult Swiss female mice received either SD or HFD and were treated daily by gavage with distilled water [control (CTL)-SD and CTL-HFD] or 0.6 µg EE2 and 60 µg DRSP (COC-SD and COC-HFD) for 65 days. COC treatment disrupted the estrous cycle, with vaginal smears showing fewer squamous cornified cells but more leukocytes, deep cells, and mucus, characteristic of metestrus and proestrus. At the end of the experiment, COC-SD females showed body weight (BW), inguinal white adipose tissue (WAT) mass, and uterus and ovary weights similar to CTL-SD. HFD increased BW and WAT mass without altering uterus and ovary weights. COC reduced HFD-induced BW and WAT gain but increased uterus weight in COC-HFD females. Morphological analysis of mammary glands revealed no pathological signs or structural changes in acini, ducts, or lumens due to COC or diet. Notably, COC-HFD females had smaller white adipocytes than CTL-HFD, while beige adipocyte levels remained unchanged across groups. These findings suggest that EE2 and DRSP may regulate HFD-induced obesity without adversely affecting mammary gland morphology.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Anais da Academia Brasileira de Ciências
- Vol. 97 (4) , e20250004
Combined oral contraceptive administration in female mice attenuated high-fat diet-induced obesity but not hepatic inflammation or fibrosis
Combined oral contraceptives (COC)s are the contraceptive method of choice for millions of women worldwide. In this study, we aimed to investigate the effects of COC administration, composed of 17α-ethinylestradiol (EE2) and drospirenone (DRSP), on obesity, glucose tolerance, and hepatic steatosis in female mice. Eighty-day-old Swiss female mice were fed either a standard diet (SD) or a high-fat diet (HFD) and daily received, via gavage, 0.2 mL of distilled water (CTL-SD and CTL-HFD groups) with or without COC (COC-SD and COC-HFD groups) for 65 days. COC administration attenuated body weight and adiposity gains and prevented glucose intolerance induced by HFD in COC-HFD females. These effects were accompanied by the upregulation of Prdm16 and Ucp-1 genes in the brown adipose tissue (BAT) of COC-HFD mice. These females also exhibited a lower hepatic steatosis score than CTL-HFD mice; however, their liver parenchyma showed an increased number of inflammatory foci, and up-regulation of the Il-1β gene. Thus, COC administration in female mice attenuated obesity development induced by HFD, possibly through modulation of BAT function, while the increased hepatic expression of the pro-inflammatory cytokine IL-1β suggests that COC exacerbated HFD-induced liver inflammation.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Anais da Academia Brasileira de Ciências
- Vol. 97 (4) , e20250004
Open AccessCombined oral contraceptive administration in female mice attenuated high-fat diet-induced obesity but not hepatic inflammation or fibrosis
Combined oral contraceptives (COC)s are the contraceptive method of choice for millions of women worldwide. In this study, we aimed to investigate the effects of COC administration, composed of 17α-ethinylestradiol (EE2) and drospirenone (DRSP), on obesity, glucose tolerance, and hepatic steatosis in female mice. Eighty-day-old Swiss female mice were fed either a standard diet (SD) or a high-fat diet (HFD) and daily received, via gavage, 0.2 mL of distilled water (CTL-SD and CTL-HFD groups) with or without COC (COC-SD and COC-HFD groups) for 65 days. COC administration attenuated body weight and adiposity gains and prevented glucose intolerance induced by HFD in COC-HFD females. These effects were accompanied by the upregulation of Prdm16 and Ucp-1 genes in the brown adipose tissue (BAT) of COC-HFD mice. These females also exhibited a lower hepatic steatosis score than CTL-HFD mice; however, their liver parenchyma showed an increased number of inflammatory foci, and up-regulation of the Il-1β gene. Thus, COC administration in female mice attenuated obesity development induced by HFD, possibly through modulation of BAT function, while the increased hepatic expression of the pro-inflammatory cytokine IL-1β suggests that COC exacerbated HFD-induced liver inflammation.